Bifunctional antibodies and their potential clinical applications

Branscomb EE, Runge MS, Savard CE, Adams KM, Matsueda GR, Haber E, Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator. Thromb Haemost 64:260, 1990 Brennan M, Davison PF, Paulus H, Preparation of bispecific antibodies by chemical recombination of monoclonal IgG1 fragments. Science 229:81, 1985 Britton KE, Mather SJ, Granowska M, Radiolabelled monoclonal antibodies in oncology. III. Radioimmunotherapy. Nucl Med Commun 12:333, 1991 Bugari G, Polesi C, Beretta A, Ghelmi S, Albertini A, Quantitative immunoenzymatic assay of human lutropin, with use of a bispecific monoclonal antibody. Clin Chem 36:47, 1990 Canevari S, Menard S, Mezzanzanica D, Miotti S, Pupa SM, Lanzavecchia A, Colnaghi MI, Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumour cell lysis by cytotoxic T-cells. Int J Cancer [Suppl 2]:18, 1988 Clark MR, Waldmann H, T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies. J Natl Cancer Inst 79:1393, 1987 Clark M, Gilliland L, Waldmann H, The potential of hybrid-hybridomas in tumour therapy. Int J Cancer [Suppl 2]:15, 1988 Clark M, Bindon C, Dyer M, Friend P, Hale G, Cobbold S, Calne R, Waldmann H, The improved lytic function and in vivo efficacy of monoclonal CD3 antibodies. Eur J Immunol 19:381, 1989 Corvalan JRF, Smith W, Gore VA, Brandon DR, Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcino-embryonic antigen (CEA) and vinca alkaloids. Cancer Immunol Immunother 24:133, 1987 Corvalan JFR, Smith W, Gore VA, Brandon DR, Ryde PJ, Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody. Cancer Immunol Immunother 24:138, 1987 Corvalan JFR, Smith W, Gore VA, Tumour therapy with vinca alkaloids targeted by a hybrid-hybrid monoclonal antibody recognising both CEA and vinca alkaloids, Int J Cancer [Suppl] 2:22, 1988 Cotton RGH, Milstein C, Fusion of two immunoglobulin-producing myeloma cells, Nature 244:42, 1973 DePalazzo IG, Gercel-Taylor C, Kitson J, Weiner LM, Potentiation of tumour lysis by a bispecifi antibody that binds to Ca19-9 antigen and the Fcγ receptor expressed by human large granular lymphocytes. Cancer Res 50:7123, 1990 Fanger MW, Segal DM, Romet-Lemonne J-L, Bispecific antibodies and targeted cellular cytotoxicity. Immunol Today 12:55, 1991 Ferrini S, Prigione I, Mammoliti S, Colnaghi MI, Menard S, Moretta A, Moretta L, Retargeting of T-cell receptor gamma/delta+ lymphocytes against tumour cells by bispecific monoclonal antibodies—induction of cytolytic activity and lymphokine production. Int J Cancer [Suppl] 4:53, 1989 Ferrini S, Prigione I, Mammoliti S, Colnaghi MI, Menard S, Moretta A, Moretta L, Retargeting of human lymphocytes expressing the T-cell receptor gamma/delta to ovarian carcinoma cells by the use of bispecific monoclonal antibodies. Int J Cancer 44:245, 1989 Ferrini S, Prigione I, Miotti S, Ciccone E, Cantoni C, Chen Q, Colnaghi MI, Moretta L, Bispecific monoclonal antibodies directed to CD16 and to a tumour associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones. Int J Cancer 48:227, 1991 French RR, Courtenay AE, Ingamells S, Stevenson GT, Glennie MJ, Cooperative mixtures of bispecific F(ab′)2 antibodies for delivering saporin to lymphoma in vitro and in vivo. Cancer Res 51:2353, 1991 Gilliland LK, Clark MR, Waldmann H, Universal bispecific antibody for targeting tumour cells for destruction by cytotoxic T-cells. Proc Natl Acad Sci USA 85:7719, 1988 Glennie MJ, McBride HM, Worth AJ, Stevenson GT, Preparation and performance of bispecific F(ab′)2 antibody containing thioether-linked Fab′γ fragments. J Immunol 139:2367, 1987 Görög G, Gandolfi A, Paradisi G, Rolleri E, Klasen E, Dressi V, Strom R, Celada F, Use of bispecific hybrid antibodies for the development of a homogeneous enzyme immunoassay. J Immunol Methods 123:131, 1989 Gridley DS, Stickney DR, Changes in leucocyte population following murine bifunctional antibody infusion in colon cancer patients. Clin Exp Immunol 84:284, 1991 Gridley DS, Stickney DR, Slater JM, Effects of murine bifunctional antibody infusion on leukocyte populations of patients with colon cancer, FASEB J 2:A695, 1988 Gridley DS, Ewart KL, Cao JD, Stickney DR, Hyperthermia enhances localization of111In-labelled hapten to bifunctional antibody in human colon tumour xenografts. Cancer Res 51:1515, 1991 Hammerling U, Aoki T, DeHarven E, Boyse EA, Old LJ, Use of hybrid antibody with anti-G and anti-ferritin specificities in locating cell surface antigens by electron microscopy. J Exp Med 128:1461, 1968 Howard JC, Butcher GW, Galfre G, Milstein C, Milstein CP, Monoclonal antibodies as tools to analyse the serological and genetic complexities of major transplantation antigens. Immunol Rev 47:139, 1979 Karawajew L, Behrsing O, Kaiser G, Micheel B, Production and ELISA application of bispecific monoclonal antibodies against fluorescein isothiocyanate (FITC) and horseradish peroxidase (HRP). J Immunol Methods 111:95, 1988 King KL, Gridley DS, Stickney DR, Autoradiographic biodistribution of bifunctional antibody111In BLEDTA IV in nude mice bearing human colon tumour. FASEB J 2:A694, 1988 Kohler G, Milstein C, Continuous culture of fused cells secreting antibody of predefined specificity. Nature 256:495, 1975 Lanzavecchia A, Scheidegger D, The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 17:105, 1987 Martinis J, Kull JF, Franz G, Bartholomew RM, Monoclonal antibodies with dual antigen specificity. In: Peeters H (ed) Protides of the biological fluids. Proceedings of the 30th colloquium, Brussels, Belgium, May, 1982. Pergamon Press, Oxford, pp 311–316, 1982 Mezzanzanica D, Canevari S, Pupa SM, Tagliabue E, Lanzavecchia A, Colnaghi MI, Human ovarian carcinoma lysis by cytotoxic T-cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int J Cancer 41:609, 1988 Milstein C, Cuello AC, Hybrid hybridomas and their use in immunohistochemistry, Nature, 305:537, 1983 Milstein C, Cuello AC, Hybrid hybridomas and the production of bispecific monoclonal antibody. Immunol Today 5:299, 1984 Nissonoff A, Mandy WJ, Quantitative estimation of the hybridisation of rabbit antibodies. Nature 194:355, 1962 Nissonoff A, Rivers MM, Recombination of a mixture of univalent antibody fragments of different specificity. Arch Biochem Biophys 93:460, 1961 Nitta T, Yagita H, Azuma T, Sato K, Okumura K, Bispecific F(ab′)2 monomer prepared with anti-CD3 and anti-tumour monoclonal antibodies is most potent in induction of cytolysis of human T-cells. Eur J Immunol 19:1437, 1989 Nolan O, O'Kennedy R, Chemical production of bifunctional antibodies, Biochem Soc Trans 20:605, 1992 Paulus H, Preparation and biomedical applications of bispecific antibodies, Behring Inst Mitt 78:118, 1985 Paya CV, McKean DJ, Segal DM, Schoon RA, Showalter SD, Leibson PJ, Heteroconjugate antibodies enhance cell-mediated anti-herpes simplex virus immunity. J Immunol 142:666, 1989 Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM, Specific targeting of cytotoxic T-cells by anti-T3 linked to antitarget cell antibody. Nature 316:354, 1985 Pimm MV, Robins RA, Embleton MJ, Jacobs E, Markham AJ, Charleston A, Baldwin RW, A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate. Br J Cancer 61:508, 1990 Pupa SS, Canevari S, Fontanelli R, Menard S, Mezzanzanica D, Lanzavecchia A, Colnaghi MI, Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells. Int J Cancer 42:455, 1988 Qian J-H, Titus JA, Andrea SM, Mezzanzanica D, Garrido MA, Wunderlich JR, Segal DM, Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumour growth. J Immunol 146:3250, 1991 Raso V, Griffin T, Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin bearing target cells. Cancer Res 41:2073, 1981 Reading C, Biologically produced bifunctional antibodies. In: Tom BH, Allison JP (eds) Hybridomas and cellular immortality. Plenum, New York, pp 235–250, 1981 Scott CF, Blättler WA, Lambert JM, Kalish RS, Mortimoto C, Schlossman SF, Requirements for the construction of antibody heterodimers for the direction of lysis of tumours by human T-cells. J Clin Invest 81:1427, 1988 Smith W, Gore VA, Brandon DR, Lynch DN, Cranstone SA, Corvalan JFR, Suppression of well established tumour xenografts by a hybrid-hybrid monoclonal antibody and vinblastine. Cancer Immunol Immunother, 31:157, 1990 Staerz UD, Bevan MJ, Hybrid-hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci USA 83:1453, 1986 Stickney DR, Fincke JM, Slater JB, Ahlem CN, Merchant B, Slater JM, Effects of perfluorochemical and carbogen on tumour metastases and phagocytic cell populations. FASEB J 2:A694, 1988 Suresh MR, Cuello AC, Milstein C, Advantages of bispecific hybridomas in one-step immunocytochemistry and in immunoassays. Proc Natl Acad Sci USA 83:7989, 1986 Tada H, Toyoda Y, Iwasa S, Bispecific antibody-producing hybrid hybridoma and its use in one-step immunoassays for human lymphotoxin. Hybridoma 8:73, 1989 Takahashi M, Fuller SA, Production of murine hybrid-hybridomas secreting bispecific monoclonal antibodies for use in urease-based immunoassays, Clin Chem 34:1693, 1988 Tsukada Y, Ohkawa K, Hibi N, Tsuzuki K, Oguma K, Satoh H, The effect of bispecific monoclonal antibodies recognising both hepatoma-specific membrane glycoprotein and anthra cycline drugs on the metastatic growth of hepatoma AH66. Cancer Biochem Biophys 10:247, 1989 Van Dijk, Tsuro T, Segal DM, Bolhuis RLH, Colognola R, Griend RJ van de, Fleuren GJ, Warnaar SO, Bispecific antibodies reactive with the multidrug-resistance related glycoprotein and CD3 induce lysis of multidrug-resistant tumour cells, Int J Cancer 44:738, 1989 Webb KS, Derivation of hybridomas secreting bifunctional monoclonal antibody recognising a prostate-restricted antigen and pokeweed anti-viral protein, Proc Am Assoc Can Res, 29:252, 1988 Webb KS, Ware JL, Parks SF, Walther PJ, Paulson DF, Evidence for a novel hybrid immunotoxin recognising ricin A-chain by one antigen-combining site and a prostate-restricted antigen by the remaining antigen-combining site: potential for immunotherapy, Cancer Treat Rep 69:663, 1985 Webb KS, Ramakrishnan S, Walther PJ, The impact of multiple hybrid immunotoxins, recognising RAC and PTX, and second stage biomodifiers of human prostate carcinoma. FASEB J 2:A629, 1988 Wong JT, Colvin RB, Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J Immunol 139:1369,1987 Zarling JM, Moran PA, Grossmarie, LS, McClure J, Shriver K, Ledbetter JA. Lysis of cells infected with HIV-1 by human lymphocytes targeted with monoclonal antibody heteroconjugates. J Immunol 140:2609, 1988